FIELD: biotechnology; medicine.
SUBSTANCE: invention refers to biotechnology and medicine, namely to oncology, and can be used for suppressing tumour growth in patients suffering colorectal cancer. Disclosed is a method for inhibiting the growth of colorectal cancer tumours in vivo by exposing a genetically modified version of the extracellular domain of TRAIL DR5-B recombinant protein, having an amino acid sequence as presented in SEQ ID NO. 1, on tumour-bearing animals, wherein DR5-B selectively binds to DR5 death receptor and causes death of tumour cells by apoptosis.
EFFECT: tumour growth inhibition reaches 41-46 % and is stably maintained at a relatively high level during 15th to 30th day after the beginning of the exposure.
1 cl, 5 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SUPPRESSING TUMOUR GROWTH | 2012 |
|
RU2530592C2 |
| NEW 9-AMINOACRIDONE DERIVATIVE WITH ANTITUMOR AND ANTIMETASTATIC ACTIVITY | 2021 |
|
RU2810783C2 |
| METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 |
|
RU2665168C1 |
| RECOMBINANT ALBUMEN WITH ANTI-CANCER EFFECT, GENE CODING IT, AND APPLICATION THEREOF | 2003 |
|
RU2333221C2 |
| POLYMER CONTAINING MEDICINAL AGENT BASED ON ANTITUMOR AGENT ETOPOSIDE | 2015 |
|
RU2595859C1 |
| METHOD FOR TUMOUR CELL DEATH INDUCTION | 2015 |
|
RU2620165C2 |
| METHOD OF LUNG CANCER TREATMENT | 2008 |
|
RU2365370C1 |
| METHOD OF TREATING MALIGNANCIES IN MAMMALS | 2011 |
|
RU2461566C1 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
